US Markets
AZN

AstraZeneca still waiting for FDA decision to resume U.S. trial

Credit: REUTERS/ANDREW KELLY

AstraZeneca is still waiting for the go-ahead from the U.S. drug regulator to restart the clinical trial of its potential COVID-19 vaccine in the United States, Chief Executive Pascal Soriot said on Thursday.

By Ludwig Burger and Caroline Copley

FRANKFURT, Sept 24 (Reuters) - AstraZeneca AZN.L is still waiting for the go-ahead from the U.S. drug regulator to restart the clinical trial of its potential COVID-19 vaccine in the United States, Chief Executive Pascal Soriot said on Thursday.

"We are the sponsor of the U.S. study. We then provided all this information to the FDA (U.S. Federal Drug Administration) and we are waiting to hear their decision," Soriot told a virtual World Economic Forum discussion.

The U.S. trial of AstraZeneca's COVID-19 vaccine candidate, initially developed by the University of Oxford, remains on hold while regulators investigate an illness in one of the participants, even after a British study and other programmes outside of the United States have resumed.

U.S. Health and Human Services Secretary Alex Azar said on Wednesday the continued suspension showed the FDA took vaccine safety seriously.

A document posted online by Oxford university last week stated the illness in a British participant that triggered the pause on Sept. 6 may not have been associated with the vaccine.

(Reporting by Ludwig Burger; Editing by Mark Potter)

((Caroline.Copley@thomsonreuters.com; +49 (0)30 2201 33584 ;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AZN

Latest Markets Videos

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More